Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 3/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.48 |
| ▸ | CDC25C | P30307 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28028637 | 0.92 | HPGD (0.49) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL846623 | 0.92 | ALDH1A1 (0.49) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL20912990 | 0.90 | ALDH1A1 (0.47) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL7925164 | 0.88 | CTNNB1 (0.47) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL25156303 | 0.85 | KMT2A (0.52) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL15203285 | 0.85 | KMT2A (0.52) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL31360448 | 0.85 | KMT2A (0.52) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL10412730 | 0.85 | ALDH1A1 (0.51) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL20514279 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL283096 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDCDC25BCDC25ACDC25C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104981154-A | Pesticidal compositions and methods related thereto | DOW AGROSCIENCES LLC | 2015-10-14 | — | — | CN | disclosed |
| US-8809373-B2 | Pyridine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809373-B2 | Pyridine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809373-B2 | Pyridine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8541431-B2 | Pyrimidine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541431-B2 | Pyrimidine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541431-B2 | Pyrimidine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130123304-A1 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-05-16 | — | — | US | disclosed |
| US-6759554-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-07-06 | — | — | US | disclosed |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | disclosed |
| CN-1267296-A | Barbituric acid derivatives with anti-metastatic and anti-tumor activities | ROCH DIAGNOSIS EQUIPMENT AG (DE) | 2000-09-20 | — | — | CN | disclosed |
| CN-1209123-A | New barbituric acid derivatives, processes for their prodn. and pharmaceutical agent contg. same | BOEHRINGER MANNHEIM GMBH (DE) | 1999-02-24 | — | — | CN | disclosed |
| US-5389616-A | Renin inhibitor, hypotensive agent | HOFFMAN-LAROCHE INC. (US) | 1995-02-14 | — | — | US | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| US-5256645-A | Renin inhibitors; hypotensive agents | HOFFMANN-LA ROCHE INC. (US) | 1993-10-26 | — | — | US | disclosed |
| US-5192797-A | Antiepileptic and anticonvulsant agents | SYNTHELABO (FR) | 1993-03-09 | — | — | US | disclosed |
| US-5134123-A | Renin enzyme inhibitors for cardiovascular disorders and high blood pressure | HOFFMAN-LA ROCHE INC. (US) | 1992-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | ALDH1A1 26/4885HPGD 613/4885CDC25B 3738/4885 |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | ALDH1A1 26/4885HPGD 613/4885CDC25B 3738/4885 |
| US-20130123304-A1 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | CNR1, CNR2, NPY1R | ALDH1A1 2138/4885HPGD 839/4885CDC25B 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.